



Title	RETRACTED: Effects of olprinone on neuromuscular blockade caused by vecuronium
Author(s)	Katayama, Takaaki; Saitoh, Yuhji; Nemoto, Chiaki; Hirama, Takahiro; Isosu, Tsuyoshi; Murakawa, Masahiro
Citation	Fukushima Journal of Medical Science. 53(2): 61-69
Issue Date	2007-12
URL	http://ir.fmu.ac.jp/dspace/handle/123456789/211
Rights	© 2007 The Fukushima Society of Medical Science
DOI	10.5387/fms.53.61
Text Version	publisher

This document is downloaded at: 2024-04-27T04:46:36Z

RETRACTED ARTICLE

The below article has been retracted.

Article title

[EFFECTS OF OLPRINONE ON NEUROMUSCULAR BLOCKADE CAUSED BY VECURONI-
UM]

Author

Takaaki Katayama, Yuhji Saitoh, Chiaki Nemoto, Takahiro Hiram, Tsuyoshi Isosu, Masahiro
Murakawa

Journal title

FUKUSHIMA JOURNAL OF MEDICAL SCIENCE Vol. 53, No. 2 2007 : 61-69

Fukushima Medical Society
Editorial Committee
July 5, 2017

EFFECTS OF OLPRINONE ON NEUROMUSCULAR BLOCKADE CAUSED BY VECURONIUM

TAKA AKI KATAYAMA¹⁾, YUHJI SAITOH²⁾, CHI AKI NEMOTO¹⁾,
TAKA HIRO HIRAMA¹⁾, TSUYOSHI ISOSU¹⁾ and MASA HIRO MURAKAWA¹⁾

¹⁾Department of Anesthesiology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan, ²⁾Department of Anesthesiology, Saitte General Hospital, Saitama, Japan

(Received November 27, 2006, accepted May 10, 2007)

Abstract : We studied the effect of olprinone on neuromuscular blockade caused by vecuronium. Thirty women undergoing nitrous oxide-oxygen-isoflurane anesthesia were randomly divided into olprinone ($n=15$) or control group ($n=15$). In the olprinone group, the patients received an intravenous initial loading dose of olprinone at a rate of $2 \mu\text{g}/\text{kg}/\text{minute}$ for 5 minutes, followed by a continuous infusion of olprinone at $0.3 \mu\text{g}/\text{kg}/\text{minute}$. In the control group, the patients received normal saline. Thirty minutes after the beginning of the infusion of olprinone or normal saline, vecuronium ($0.1 \text{ mg}/\text{kg}$) was administered. The degree of neuromuscular blockade was monitored electromyographically at the adductor pollicis muscle. The time to the onset of neuromuscular blockade, and to the return of the first, second, third, or fourth response in train-of-four (TOF; T1, T2, T3, or T4, respectively), and the time course of recovery of T1/control did not differ significantly between the groups. After 50-70 minutes of vecuronium, the TOF ratio (T4/T1) in the olprinone group was significantly higher than in the control group. During this period, the mean TOF ratios in the control and olprinone groups were 0.15-0.39 and 0.40-0.57, respectively. In conclusion, olprinone accelerates the recovery of the TOF ratio, and the quickening effect of olprinone on the recovery of the TOF ratio may be apparent 50-70 minutes after vecuronium in anesthetized patients receiving vecuronium.

Key words : olprinone, vecuronium, train-of-four

INTRODUCTION

Olprinone and milrinone are phosphodiesterase (PDE) III inhibitors that are

片山貴晶, 斎藤祐司, 根本千秋, 平間孝広, 五十洲剛, 村川雅洋

Corresponding author : Takaaki Katayama E-mail : yamanobori3192@yahoo.co.jp

commonly administered in patients with acute heart failure, due to their vasodilatory and positive inotropic effects¹⁻⁶). The cardiovascular effects of PDE III inhibitors are attributed to inhibition of PDE III and perpetuation of intracellular cyclic adenosine monophosphate activity. Recent studies have demonstrated that PDE III inhibitors can influence the function of extracardiac organs, such as the diaphragm or skeletal muscle⁷⁻¹²). Milrinone has been reported to antagonize the effect of non-depolarizing neuromuscular relaxants in the rat nerve hemidiaphragm preparations⁷). In the clinical setting, milrinone accelerates the recovery from neuromuscular blockade induced by vecuronium in anesthetized patients⁸). It has been demonstrated that olprinone and milrinone can enhance the contractility of the fatigued dog diaphragm, and that olprinone is more potent than milrinone⁹⁻¹²). We therefore hypothesized that the recovery of contraction of the skeletal muscles after administration of a neuromuscular relaxant may be accelerated by the administration of olprinone. However, no previous studies have examined the effect of olprinone on neuromuscular blockade in humans. The purpose of this study was to examine the effect of olprinone on neuromuscular blockade caused by vecuronium in anesthetized patients.

MATERIALS AND METHODS

This protocol was approved by the Fukushima Medical University ethics committee, and written informed consent was obtained from each patient. Thirty adult females, with American Society of Anesthesiologists (ASA) physical status I or II, scheduled for elective surgery (mastectomy), orthopedic surgery (total knee replacement), ear nose throat surgery (tympanoplasty), or ophthalmologic surgery (segmental buckling or vitrectomy) under general anesthesia were enrolled in this study. The patients were randomly allocated to two groups of 15 patients each: olprinone group or control group.

Administration of olprinone or normal saline

Premedication consisting of 0.01 mg/kg atropine and 0.05 mg/kg midazolam was administered intramuscularly one hour before the induction of anesthesia. In the olprinone group, 30 minutes before induction of anesthesia, an initial loading dose of olprinone was administered at 2 μ g/kg/minute for 5 minutes, followed by a maintenance dose of olprinone at 0.3 μ g/kg/minute. These doses were similar to those reported previously¹⁻⁴). Since the plasma concentration of olprinone has been reported to stabilize 30 minutes after the beginning of infusion in humans¹¹), we began to administer olprinone 30 minutes before the induction of anesthesia. In the control group, normal saline was given as a placebo, instead of olprinone, at a rate of 0.1 ml/kg/hour for 5 minutes, and thereafter, the infusion rate was reduced to 0.015 ml/kg/hour. Electrocardiograph, non-invasive blood pressure cuff, and pulse oximeter as part of the anesthetic machine (AS/3, ADU Anaesthetic Work Station,

Datex Inc., Helsinki, Finland) were attached to the patients in each of the two groups.

Monitoring of the degree of neuromuscular blockade

Thirty minutes after the beginning of the infusion of olprinone or normal saline, anesthesia was induced with intravenous thiopental 4 mg/kg and fentanyl 2 μ g/kg. After loss of the eyelash reflex was confirmed, the degree of neuromuscular blockade was monitored electromyographically using a neuromuscular transmission monitor (Relaxograph; Datex Inc., Helsinki, Finland). Two surface stimulating electrodes were placed over the ulnar nerve at the wrist and two surface recording electrodes were placed over the adductor pollicis muscle. One ground electrode was attached between the stimulating and recording electrodes. Train-of-four (TOF) stimuli, each stimulus consisting of a 0.2 millisecond duration square-wave at a frequency of 2 Hz, were delivered every 20 seconds at a supramaximal current, and the amplitude of the evoked electromyographic responses were measured at the adductor pollicis muscle. TOF stimuli were applied every 20 seconds for approximately 5 minutes until the amplitude of the electromyographic responses stabilized. The electromyographic amplitude in response to T1 was regarded as the control. Thereafter, vecuronium 0.1 mg/kg was administered intravenously to facilitate tracheal intubation. The disappearance of the response to T1 (1st response in TOF) was regarded as the onset of neuromuscular blockade. The times from the administration of vecuronium to the onset of neuromuscular blockade were compared between the two groups. The times from the injection of vecuronium to the return of T1, T2, T3, or T4 (the 1st, 2nd, 3rd, or 4th response in TOF) were also compared between the groups. T1/control and train-of-four ratio (TOF ratio, ratio of the electromyographic amplitude of T4 to that of T1) were recorded every 10 minutes, and were compared between the two groups. The TOF electromyographically measured responses were displayed on the anesthetic machine, and were recorded by an anesthetist blinded to the nature of the infusion.

Anesthetic management

In each group, anesthesia was maintained with nitrous oxide 66%, oxygen 33%, and 0.5% end-tidal isoflurane. Additionally, when the patients exhibited systolic hypertension (systolic arterial pressure > 150 mmHg) or tachycardia (heart rate > 100 bpm), a bolus dose of fentanyl 1-2 μ g/kg was administered intravenously. Ventilation was controlled to maintain normocapnia ($P_{ET}CO_2$ 30-37 mmHg). The concentrations of anesthetics and $P_{ET}CO_2$ were measured using a multiple gas monitor attached to the anesthetic machine. A forced-air warming device (Warm Touch, model 5200, Tyco Healthcare Japan, Tokyo, Japan) was positioned over the patients' arms and hands during surgical procedure. The peripheral temperature over the adductor pollicis muscle was monitored using a surface skin thermometer (First Temp Genius, Nippon-Sherwood Inc., Tokyo, Japan).

Statistical analyses

All results were expressed as the number or mean \pm SD. Patient data, time to the onset of neuromuscular blockade, and the times to the return of T1, T2, T3, or T4 were compared between the two groups using unpaired *t*-test. Recoveries of T1/control or TOF ratio were compared between the two groups using analysis of variance (ANOVA) and unpaired *t*-test with Bonferroni's adjustment. *P*-values < 0.05 were considered to be statistically significant. Statistical analyses were performed using a statistical package (SYSTAT 8.0 ; SPSS Inc., Chicago, USA) on a personal computer.

RESULTS

Patient characteristics

Table 1 shows the characteristics of the patients between the two groups. The age, weight, and height of the patients were similar between the two groups.

Monitoring of the degree of neuromuscular blockade

The onset of neuromuscular blockade in the olprinone group did not differ significantly from that in the control group (241 ± 60 vs 221 ± 38 seconds, $n = 15$, $P =$

Table 1. Characteristics of the female patients studied in the two groups.

	Control	Olprinone	<i>P</i> -value
Number (n)	15	15	
Age (yrs)	58 ± 14	51 ± 14	0.224
Weight (kg)	54 ± 8	53 ± 7	0.685
Height (cm)	158 ± 7	154 ± 7	0.208

Values are the number or mean \pm SD. No significant difference was observed between the two groups.

Table 2. Time from the administration of vecuronium 0.1 mg/kg to the return of T1, T2, T3, or T4 in the two groups.

	Control	Olprinone	<i>P</i> -value
T1 (minutes)	26.3 ± 7.7	22.8 ± 7.2	0.205
T2 (minutes)	35.4 ± 9.4	31.1 ± 8.8	0.211
T3 (minutes)	40.6 ± 10.9	35.1 ± 9.6	0.151
T4 (minutes)	43.7 ± 11.6	36.5 ± 10.3	0.086

Values are the mean \pm SD. No significant difference was observed between the two groups.




Figure 1. T1/control obtained in the olprinone (●) and control (○) groups. No significant difference was observed between the groups.




Figure 2. TOF ratio obtained in the olprinone (●) and control (○) groups. * $P < 0.05$ between groups.

0.282).

Table 2 indicates the time from administration of vecuronium to the return of T1, T2, T3, or T4 in the two groups. The time to the return of T1, T2, T3, or T4 did not differ significantly between the two groups.

Figures 1 and 2 present the recovery of T1/control and that of TOF ratio in the two groups, respectively. As described in Figure 1, T1/control did not differ significantly between the two groups. As shown in Figure 2, 50, 60, and 70 minutes after the administration of vecuronium, the TOF ratio in the olprinone group was significantly higher than that in the control group ($P < 0.05$).

Anesthetic management

During the administration of olprinone or normal saline, none of the patients

exhibited severe hypertension (systolic arterial pressure > 180 mmHg) or hypotension (systolic arterial pressure < 80 mmHg), severe tachycardia (heart rate > 120 bpm), bradycardia (heart rate < 50 bpm), or arrhythmia. The rectal temperature and the peripheral temperature over the adductor pollicis muscle did not decrease to less than 35.5°C and 32.0°C, respectively, in any patient. In all patients the anesthesia and surgical procedures were performed uneventfully.

DISCUSSION

This study shows that during a continuous administration of olprinone, the onset of neuromuscular blockade by 0.1 mg/kg vecuronium was not affected. Olprinone did not accelerate the return of T1, T2, T3, or T4, or recovery of T1/control, but did increase the recovery of TOF ratio in anesthetized patients receiving vecuronium.

It was reported that the TOF ratio represented the degree of neuromuscular blockade at the prejunctional region of the neuromuscular junction¹³⁾. By contrast, the time to return of T1, T2, T3, or T4, and T1/control (twitch response) are related to the postjunctional effect of neuromuscular blockade¹³⁾. This study demonstrated that continuous administration of olprinone accelerated the recovery of the TOF ratio, but did not affect the time to the return of T1, T2, T3, or T4, or the recovery of the T1/control. From this viewpoint, olprinone is considered to act mainly at the prejunctional region of the neuromuscular junction, i.e., motor nerve endings, and accelerate the recovery of the TOF ratio. In fact, it was previously shown that PDE III inhibitors selectively blocked the type-1 adenosine receptor (A1-receptor)^{14,15)}. Nagano and colleagues¹⁶⁾ found that blockade of the A1-receptor causes an increase in the release of acetylcholine at the motor nerve endings. Silinsky and colleagues¹⁷⁾ also demonstrated that if PDE was inhibited, the degradation of cyclic adenosine monophosphate decreased, which resulted in an increase in acetylcholine release. When the acetylcholine release increases, the contraction of the skeletal muscle is strengthened¹⁸⁾. In this way, olprinone, a PDE III inhibitor, increases acetylcholine release at the motor nerve endings, resulting in rapid recovery of the TOF ratio.

As noted above, the blockade of twitch response is regarded as a postjunctional effect of neuromuscular relaxants¹³⁾. Uemura and colleagues¹⁹⁾ reported that an administration of olprinone did not improve twitch response in the guinea pig diaphragm. Their finding supports the present result that the time to the return of T1, T2, T3, or T4, and the blockade of T1/control, which indicated the postjunctional neuromuscular blocking effect, did not change during infusion of olprinone.

In the present study, we administered olprinone 30 minutes prior to the induction of anesthesia, because the plasma concentration of olprinone was reported to stabilize 30 minutes after the beginning of infusion in humans¹⁾. If continuous administration of olprinone was not initiated prior to the induction of anesthesia, the olprinone-induced accelerating effect on the recovery of neuromuscular blockade

might be less apparent than that observed in the present study.

In this study, the TOF ratio in the olprinone group was significantly higher than in the control group only after 50–70 minutes of administration of vecuronium. We cannot explain the reason why the TOF ratio in the olprinone group was increased 50–70 minutes after vecuronium. However, we postulate two potential explanations. First, 50–70 minutes after vecuronium, the mean TOF ratios in the control and olprinone groups were 0.15–0.39 and 0.40–0.57, respectively. We consider that the olprinone-induced effect on neuromuscular blockade may be apparent when the degree of neuromuscular blockade is relatively deep, i.e., TOF ratios in the control group were 0.15–0.39. This result is likely comparable to the previous finding that milrinone accelerated the recovery of the TOF response when the level of neuromuscular blockade was profound⁹. Second, the time course of the olprinone-induced quickening effect on recovery from neuromuscular blockade should be taken into consideration. Several previous studies have previously investigated the time course of the olprinone-induced effect. Hirota and colleagues²⁰ showed that infusion of olprinone rapidly decreased the peak airway pressure in asthmatic patients. Seki and colleagues²¹ demonstrated that 20 minutes after the administration of olprinone, there was a significant increase in cardiac output and a significant decrease in systemic vascular resistance. Based on these previous findings, the olprinone-induced accelerating effect on recovery from neuromuscular blockade may have a rapid onset. However, in this study, as described above, the TOF ratio in the olprinone group was significantly higher than that in the control group 50–70 minutes after vecuronium. In other words, the difference in the TOF ratio became significant between the two groups 80–100 minutes after the beginning of the infusion of olprinone because the continuous administration of olprinone was initiated 30 minutes before the injection of vecuronium. Thus, although the onset of the olprinone-induced effect on the bronchial smooth muscle, cardiac output, or systemic vascular resistance is rapid, that on the skeletal muscle may be slow. To avoid prolonged neuromuscular blockade by vecuronium, infusion of olprinone is considered to be of clinical use.

Kimata and colleagues²⁾ demonstrated that olprinone increased cardiac output in humans. The increase in cardiac output accelerated the onset of neuromuscular blockade since the high cardiac output resulted in quick delivery of neuromuscular relaxant to the skeletal muscles²²). However, in this study, the onset of vecuronium-induced neuromuscular blockade did not differ significantly between the two groups. Although olprinone is considered to speed the delivery of vecuronium to the adductor pollicis muscle, it may simultaneously make the skeletal muscle resistant to vecuronium because of the increase in the release of acetylcholine. For this reason, olprinone might not alter the time to the onset of neuromuscular blockade.

The degree of the paralyzing effect of neuromuscular relaxants differs between the sexes. The ED₅₀, ED₉₀, and ED₉₅ of vecuronium are less in females than in males²³). Also, the duration of action of vecuronium is longer in females than in

males²³⁾. To exclude any sex-related differences in the action of vecuronium, only female patients were studied in the present study. It is likely that if males were studied in addition to females, the main results of this study might have been changed.

We conclude that in anesthetized patients receiving vecuronium, olprinone does not affect the onset of neuromuscular blockade, time to the return of T1, T2, T3, or T4, and recovery of T1/control, but hastens the recovery of the TOF ratio. This is likely because olprinone increases the release of acetylcholine at the prejunctional region of the neuromuscular junction, but does not act at the postjunctional region of the neuromuscular junction.

ACKNOWLEDGMENTS

This research was supported by a grant from the Fukushima Society for the Promotion of Medicine.

REFERENCES

1. Atarashi H, Sasaki H, Ohsaka M, Sasaki Y, Hayakawa H, Tomono Y, Morishita N. A phase I study of E-1020 — intravenous injection. *Jpn J Clin Pharmacol Ther*, **21** : 613-621, 1990.
2. Kimata S, Hirokawa K, Kasanuki H, Takano T, Serizawa T, Sasayama S, Kumada T, Hori S, Hiramori K. Clinical effects of olprinone on acute heart failure: evaluation of acute hemodynamic effects of bolus injection and continuous infusion. *Rinshyoo To Kenkyuu (Jpn J Clin Exp Med)*, **69** : 2260-2274, 1992.
3. Takaoka H, Takeuchi M, Odake M, Hayashi Y, Mori M, Hata K, Yokoyama M. Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseased human heart. *J Am Coll Cardiol*, **22** : 598-606, 1993.
4. Sha K, Iwata M, Mori M, Motozu Y, Yonemoto N, Kitaguchi K, Hirai K, Furuya H. Evaluation of the different doses of olprinone for continuous infusion after cardiopulmonary bypass for coronary artery bypass surgery. *Masui (Jpn J Anesthesiol)*, **52** : 621-625, 2003.
5. Ogawa T, Ohnara H, Tsunoda H, Kuroki J, Shoji T. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridine-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles. *Arzneim Forsch Drug Res*, **39** : 33-37, 1989.
6. Ohnara H, Ogawa T, Takeda M, Katoh H, Daiku Y, Igarashi T. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridine-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs. *Arzneim Forsch Drug Res*, **39** : 38-45, 1989.
7. Konstam MA, Cody RJ. Short-term use of intravenous milrinone for heart failure. *Am J Cardiol*, **75** : 822-826, 1995.
8. Nakajima H, Hattori H, Aoki K, Katayama T, Saitoh Y, Murakawa M. Effect of milrinone on vecuronium-induced neuromuscular block. *Anaesthesia*, **58** : 643-646, 2003.
9. Fujii Y, Takahashi S, Toyooka H. The effects of milrinone and its mechanism in the fatigued diaphragm in dogs. *Anesth Analg*, **87** : 1077-1082, 1998.

10. Fujii Y, Takahashi S, Toyooka H. The effects of olprinone compared with milrinone on diaphragmatic muscle function in dogs. *Anesth Analg*, **89**: 781-785, 1999.
11. Fujii Y, Toyooka H. Different effects of olprinone on contractility in nonfatigued and fatigued diaphragm in dogs. *Can J Anesth*, **47**: 1243-1248, 2000.
12. Uemura A, Fujii Y, Toyooka H. Inhaled olprinone improves contractility of fatigued canine diaphragm. *Br J Anaesth*, **88**: 408-411, 2002.
13. Saitoh Y, Toyooka H, Amaha K. Recoveries of post-tetanic twitch and train-of-four responses after administration of vecuronium with different inhalation anaesthetics and neuroleptanaesthesia. *Br J Anaesth*, **70**: 402-404, 1993.
14. Parsons WJ, Ramkumar V, Stiles GL. The new cardiotonic agent sulmazole is an A1 adenosine receptor antagonist and functionally blocks the inhibitory regulator, Gi. *Mol Pharmacol*, **33**: 441-448, 1988.
15. Ungerer M, Böhm M, Schwinger RHG, Erdmann E. Antagonism of novel inotropic agents at A₁ adenosine receptors and m-cholinoceptors in human myocardium. *Naunyn Schmiedebergs Arch Pharmacol*, **341**: 577-585, 1990.
16. Nagano O, Földes FF, Nakatsuka H, Reich D, Ohta Y, Sperlagh B, Vizi ES. Presynaptic A₁-purinoceptor-mediated inhibitory effects of adenosine and its stable analogues on the mouse hemidiaphragm preparation. *Naunyn Schmiedebergs Arch Pharmacol*, **346**: 197-202, 1992.
17. Silinsky EM. On the mechanism by which adenosine receptor activation inhibits the release of acetylcholine from motor nerve endings. *J Physiol*, **346**: 243-256, 1984.
18. Saitoh Y, Fujii Y, Oshima T. The ulinastatin-induced effect on neuromuscular block caused by vecuronium. *Anesth Analg*, **89**: 1565-1569, 1999.
19. Uemura A, Fujii Y, Toyooka H, Suzuki S, Sawada K, Adachi H. Olprinone for treatment, but not prevention, of fatigue-induced changes in guinea-pig diaphragmatic contractility. *Anesth Analg*, **96**: 1679-1682, 2003.
20. Hirota K, Kabara S, Hashimoto H, Ishihara H, Matsuki A. Use of olprinone, a phosphodiesterase III inhibitor, in an asthmatic patient. *Acta Anaesthesiol Scand*, **45**: 510-512, 2001.
21. Seki M, Mizushige K, Ueda T, Kitadai M, Matsuo H. Effect of olprinone, a phosphodiesterase III inhibitor, on arterial wall distensibility: differentiation between aorta and common carotid artery. *Heart Vessels*, **14**: 224-231, 1999.
22. Donati F. Onset of action of relaxants. *Can J Anesth*, **35**: S52-58, 1988.
23. Xue FS, Liao X, Liu JH, *et al.* Dose-response curve and time-course of effect of vecuronium in male and female patients. *Br J Anaesth*, **80**: 720-724, 1998.